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In modern medicine the resistance to conventional antibiotics is becoming a serious concern due to high instances of 
mortality. Several metallic nanoparticles are suggested as promising anti-microbial agents against multidrug-resistant 
bacteria and some viruses. Among the nanoparticles mentioned, we review the recent finding which demonstrate the 
impact of silver nanoparticles on antimicrobial activities and recommend them as a potential candidate for restraining 
infections. 
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A recent report has shown that methicillin-resistant 
Staphylococcus aureus was detected in high proportions 
between 28~63% in hospitals of Asia and South Africa (1), 
the number of infection-related hospitalizations with anti- 
biotic resistance has also increased 359% during the 10-year 
period in the United States (2). The various and complicated 
mechanisms of antibiotics resistance make conventional 
treatment difficult for the eradication of such infections. 
Therefore, other strategies are required to overcome drug 
resistant microorganisms. 
Historically silver salts have been used for infections 
such as syphilis and gonorrhea (3) and nowadays the use of 
silver has extended to treat a range of other microorganism 
including human pathogens. Recently, due to the advance- 
ment of nanotechnology, size-controlled silver nanoparticles 
have been produced in a large scale at industrial sites or 
laboratories, which has leads to the wide application of 
silver nanoparticles as broad spectrum antimicrobial agents. 
Contrary to the effects of ionic silver, the antimicrobial 
activity of silver particles is determined by the dimensions 
of the particles. Small particles have greater antimicrobial 
effect than large particles. One recent paper shows that the 
minimum inhibitory concentration (MIC) of silver nano- 
particles (mean diameter of 9 nm) against Gram positive S. 
aureus and Gram negative Escherichia coli were 180 μg/ml 
and 15 μg/ml, respectively (4). When compared, silver 
sulfadiazine silver nanoparticles were more effective with a 
significantly lower risk for percutaneous absorption of 
silver ions (5). The other report shows that the MIC of 
smaller silver nanoparticles (mean diameter of 9~14 nm) 
have lower MIC (14~28 μg/ml) to E. coli, Pseudomonas 
aeruginosa and S. aureus than those of larger particles 
(mean diameter of 24~30 nm), which are 215~258 μg/ml 
(6). But the assay methods also influence the bactericidal 
activities. When the same 10 nm silver nanoparticles were 
used, E. coli was more sensitive than Bacillus subtilis in 
the growth inhibition and colony forming unit (CFU) assays, 
whereas B. subtilis was more sensitive than E. coli in the 
liquid-to-plate assay (7). 
The exact mechanisms of antimicrobial or toxicity 
177 
  Received: May 10, 2012/ Revised: May 29, 2012 
Accepted: June 4, 2012 
 *Corresponding author: In-Hong Choi. Department of Microbiology,
Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, 
Seoul 120-752, Korea. 
Phone:  +82-2-2228-1821, Fax:  +82-2-392-7088 
e-mail:  inhong@yuhs.ac 
**This work is supported by Nano Material Technology Development
Program through the National Research Foundation of Korea (NRF)
funded by the Ministry of Education, Science and Technology (2011-
001916 and 2012-0006195). 
 Letter to the Editor
178 E-J Yang, et al. 
 
activities by silver nanoparticles are still in investigation. 
The positive charge on the Ag ion is suggested crucial for 
antimicrobial activity. Some literature shows that the 
electrostatic attraction between negatively charged bacterial 
cells and positively charged nanoparticles is responsible (8). 
These nanoparticles have been shown to accumulate inside 
the membrane and can subsequently penetrate into the cells 
causing damage of cell wall or cell membranes (9). Other 
mechanisms involving interaction of silver molecules with 
biological macromolecules such as enzymes and DNA 
through an electron-release mechanism (10) or free radical 
production (11) have been proposed. Some literatures suggest 
inhibition of cell wall synthesis as well as protein synthesis 
has been shown to be induced by silver nanoparticles with 
the proteomic data showing evidence of accumulation of 
envelope protein precursor or destabilization of outer 
membrane, which finally leads to ATP leaking (12). 
During the past decade, the application of silver 
nanoparticles in wound dressing has dramatically increased 
as a preferred treatment for infected wounds, including 
burn wounds (13, 14). Silver infused wound dressing 
shows efficient bactericidal activities against routine isolates 
from burn wounds. Forty-nine antibiotic-resistant bacteria 
including vancomycin-resistant Enterococcus faecium, 
methicillin-resistant S. aureus, multidrug-resistant (MDR) 
P. aeruginosa, MDR Vibrio spp., extended-spectrum 
β-lactamase producing Salmonella spp., ESBL producing 
Klebsiella pneumoniae, ESBL producing Proteus mirabilis, 
ESBL producing E. coli and MDR Acinetobacter baumannii 
show susceptibility to the antimicrobial activities over all 
pH ranges although all of which are more susceptible in 
instances of higher pH acidity levels (15). Some dressings 
have been modified to work more efficiently. A biological 
dressing containing silver-impregnated polyelectrolyte multi- 
layers was revealed to reduce bacterial burdens significantly 
in murine skin wounds (16). Dressings with chitosan-based 
composite sponge containing silver nanoparticles have also 
proven to possess bacteriostatic and bactericidal properties 
against S. aureus, E. coli and P. aeruginosa (17). Further- 
more biocomposite films composed of chitosan sago starch 
and silver nanoparticles showed faster healing patterns 
compared to the untreated control, which suggests that this 
film may be applicable not only as a dressing material for 
wound healing but also for bactericidal purpose (18). These 
wound healing results are supported by our report that 
silver nanoparticles induce angiogenesis with induction of 
vascular endothelial growth factor and nitric oxide in the 
animal model (19). Some silver nanoparticles are more 
effectively modified when prepared in thermosensitive gel 
(20) or in a disc carrier (21) to improve their medical 
applications. 
In addition to their antibacterial activities, silver nano- 
particles are also reported to have antiviral properties. 
Silver nanoparticles are known to bind envelope protein 
gp120 of human immunodeficiency virus to interfere viral 
binding to CD4+ T cells (22). Silver nanoparticles also bind 
extracellular virions of hepatitis B viruses or inhibit RNA 
synthesis of these viruses (23). The inhibitory effect of 
silver nanoparticles for replication of influenza virus by 
inhibiting fusion of viral membranes (24) and inhibition of 
early phase replication of Tacaribe virus (25) have also been 
reported. 
In conclusion, the importance of silver nanoparticles is 
clearly demonstrated by their broad-spectrum antimicrobial 
activity; their wide application as a topical agent applied to 
cervical tissues or to mucous membrane is also promising. 
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